Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type K-... von SIU, Lillian L, SHAPIRO, Jeremy D, NOTT, Louise M, CHARPENTIER, Danielle, LIAUW, Winston, SAWYER, Michael B, JEFFORD, Michael, MAGOSKI, Nadine M, HAYDON, Andrew, WALTERS, Ian, RINGASH, Jolie, DONGSHENG TU, JONKER, Derek J, O'CALLAGHAN, Chris J, KARAPETIS, Chris S, ZALCBERG, John R, SIMES, John, COUTURE, Felix, MOORE, Malcolm J, PRICE, Timothy J, SIDDIQUI, Jehan

Volltext

Health-Related Quality of Life in Patients With Advanced Colorectal Cancer Treated With Cetuximab: Overall and KRAS-Specific Results of the NCIC CTG and AGITG CO.17 Trial von Au, Heather-Jane, Karapetis, Christos S., O'Callaghan, Chris J., Tu, Dongsheng, Moore, Malcolm J., Zalcberg, John R., Kennecke, Hagen, Shapiro, Jeremy D., Koski, Sheryl, Pavlakis, Nick, Charpentier, Danielle, Wyld, David, Jefford, Michael, Knight, Gregory J., Magoski, Nadine M., Brundage, Michael D., Jonker, Derek J.

Volltext

Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial von Jonker, Derek J, Nott, Louise, Yoshino, Takayuki, Gill, Sharlene, Shapiro, Jeremy, Ohtsu, Atsushi, Zalcberg, John, Vickers, Michael M, Wei, Alice C, Gao, Yuan, Tebbutt, Niall C, Markman, Ben, Price, Timothy, Esaki, Taito, Koski, Sheryl, Hitron, Matthew, Li, Wei, Li, Youzhi, Magoski, Nadine M, Li, Chiang J, Simes, John, Tu, Dongsheng, O'Callaghan, Christopher J

Volltext

Identification of human lung and skin proteins conjugated with hexamethylene diisocyanate in vitro and in vivo von WISNEWSKI, Adam V, SRIVASTAVA, Ranjana, HERICK, Christina, LAN XU, LEMUS, Ranulfo, CAIN, Hilary, MAGOSKI, Nadine M, KAROL, Meryl H, BOTTOMLY, Kim, REDLICH, Carrie A

Volltext

The CCTG CO.26 trial: A phase II randomized study of durvalumab plustremelimumab and best supportive care (BSC) vs BSC alone in patients with advanced colorectal carcinoma (CRC) re... von Chen, Eric Xueyu, Jonker, Derek J., Kennecke, Hagen F., Koski, Sheryl L., Wei, Alice Chia-chi, Magoski, Nadine M, Tu, Dongsheng, O'Callaghan, Christopher J.

Volltext

CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory col... von Chen, Eric Xueyu, Jonker, Derek J., Kennecke, Hagen F., Berry, Scott R., Couture, Felix, Ahmad, Chaudhary E., Goffin, John R., Kavan, Petr, Harb, Mohammed, Colwell, Bruce, Samimi, Setareh, Samson, Benoit, Abbas, Tahir, Aucoin, Nathalie, Aubin, Francine, Koski, Sheryl L., Wei, Alice Chia-chi, Magoski, Nadine M, Tu, Dongsheng, O'Callaghan, Christopher J.

Volltext

The NCIC CTG and AGITG CO.23 trial: A phase III randomized study of BBI608 plus best supportive care (BSC) versus placebo (PBO) plus BSC in patients (Pts) with pretreated advanced... von Jonker, Derek J., Nott, Louise M., Yoshino, Takayuki, Li, Chiang, Gill, Sharlene, Shapiro, Jeremy David, Ohtsu, Atsushi, Zalcberg, John Raymond, Vickers, Michael M., Simes, John, Wei, Alice Chia-chi, Mittmann, Nicole, Magoski, Nadine M, Murray, Yvonne, Tsobanis, Eric, Tu, Dongsheng, Kerstein, David, O'Callaghan, Christopher J.

Volltext

Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type... von Siu, Lillian L., Shapiro, Jeremy David, Jonker, Derek J., Karapetis, Christos Stelios, Zalcberg, John Raymond, Simes, John, Couture, Felix, Moore, Malcolm J., Price, Timothy Jay, Siddiqui, Jehan, Nott, Louise M., Charpentier, Danielle, Liauw, Winston S., Sawyer, Michael B., Jefford, Michael, Magoski, Nadine M, Haydon, Andrew Mark, Walters, Ian B., Tu, Dongsheng, O'Callaghan, Christopher J.

Volltext

Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory K-RAS wild-type (WT)... von Siu, Lillian L., Shapiro, Jeremy D., Jonker, Derek J., Karapetis, Christos Stelios, Zalcberg, John Raymond, Simes, John, Couture, Felix, Moore, Malcolm J., Price, Timothy Jay, Siddiqui, Jehan, Nott, Louise M., Charpentier, Danielle, Liauw, Winston S., Sawyer, Michael B., Jefford, Michael, Magoski, Nadine M, Haydon, Andrew Mark, Walters, Ian B., Tu, Dongsheng, O'Callaghan, Christopher J.

Volltext

Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial von Mittmann, Nicole, Au, Heather-Jane, Tu, Dongsheng, O'Callaghan, Christopher J., Isogai, Pierre K., Karapetis, Christos S., Zalcberg, John R., Evans, William K., Moore, Malcolm J., Siddiqui, Jehan, Findlay, Brian, Colwell, Bruce, Simes, John, Gibbs, Peter, Links, Matthew, Tebbutt, Niall C., Jonker, Derek J.

Volltext